GITSN, Inc. (XKON:289860)

Verve Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2021	FY 2020	FY 2016	FY 2015
Period Ending	Dec 31, 2021	Dec 31, 2020	Dec 31, 2016	Dec 31, 2015
Operating Revenue	9,485	6,486	5,264	4,825
Other Revenue	-0	0	-	-0
Revenue	9,485	6,486	5,264	4,825
Revenue Growth (YoY)	46.24%	23.20%	9.11%	-
Cost of Revenue	2,994	1,692	4,220	2,983
Gross Profit	6,490	4,794	1,044	1,842
Selling, General & Admin	5,283	3,649	1,524	1,403
Research & Development	666.57	821.38	117.4	223.53
Other Operating Expenses	17.91	8.01	12.65	25.11
Operating Expenses	6,213	5,525	3,068	1,999
Operating Income	277.14	-731.61	-2,024	-156.75
Interest Expense	-77.15	-45.94	-437.33	-344.52
Interest & Investment Income	32.75	27.31	0.9	6.86
Currency Exchange Gain (Loss)	-	0.28	-	-
Other Non Operating Income (Expenses)	1.8	-5.36	-97.06	181.51
EBT Excluding Unusual Items	234.53	-755.32	-2,557	-312.89
Gain (Loss) on Sale of Investments	-	-3.08	-0.01	-
Gain (Loss) on Sale of Assets	2.68	-2.4	-	-
Asset Writedown	-	-1,943	-2,162	-31.67
Other Unusual Items	-	-	-	150.49
Pretax Income	237.21	-2,704	-4,720	-194.07
Net Income	237.21	-2,704	-4,720	-194.07
Net Income to Common	237.21	-2,704	-4,720	-194.07
Shares Outstanding (Basic)	7	7	6	6
Shares Outstanding (Diluted)	7	7	6	6
Shares Change (YoY)	8.57%	9.08%	6.44%	-
EPS (Basic)	32.00	-396.00	-754.00	-33.00
EPS (Diluted)	32.00	-396.00	-754.00	-33.00
Free Cash Flow	-1,293	268.15	-200.83	-1,334
Free Cash Flow Per Share	-174.47	39.27	-32.09	-226.92
Gross Margin	68.43%	73.91%	19.84%	38.18%
Operating Margin	2.92%	-11.28%	-38.44%	-3.25%
Profit Margin	2.50%	-41.69%	-89.65%	-4.02%
Free Cash Flow Margin	-13.64%	4.13%	-3.82%	-27.66%
EBITDA	545.36	-446.52	-1,531	87.54
EBITDA Margin	5.75%	-6.88%	-29.08%	1.81%
D&A For EBITDA	268.22	285.09	492.79	244.29
EBIT	277.14	-731.61	-2,024	-156.75
EBIT Margin	2.92%	-11.28%	-38.44%	-3.25%
Advertising Expenses	85.79	48.64	29.94	0.67

Source: S&P Global Market Intelligence. Standard template. Financial Sources.